文献速递心脑血管急症重症综合管理与镇静镇痛

血管造影衍生的血流储备分数与冠状动脉造影指导瓣膜手术合并冠心病患者冠状动脉旁路移植术:FAVOR IV-QVAS 多中心三盲随机试验

Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial.
PubMed 文献 · Lancet · 2026-01-01
一句话结论瓣膜手术合并冠心病患者中,以血管造影衍生 FFR≤0.80 指导选择性 CABG 较解剖指导(狭窄≥50%)降低 30 天复合终点(7.8% vs 13.4%,RR 0.58)。

FAVOR IV-QVAS 是在中国 12 家三级医院开展的多中心、三盲、随机试验,纳入 793 例≥18 岁、计划行瓣膜手术且至少一支主要冠状动脉存在临床显著狭窄的患者,1:1 随机接受生理指导 CABG(血管造影衍生 FFR≤0.80 的病变)或解剖指导 CABG(冠状动脉造影示狭窄直径≥50% 的病变)。主要终点为术后 30 天内死亡、心肌梗死、卒中、非计划冠状动脉血运重建和需透析的新发肾衰竭的复合终点,生理指导组 7.8% vs 解剖指导组 13.4%(绝对差异 -5.6 个百分点,95%CI -9.9 至 -1.3;RR 0.58,95%CI 0.38 至 0.89;P=0.011)。中位随访 27 个月,关键次要终点生理指导组 20.7% vs 解剖指导组 26.8%(HR 0.74,95%CI 0.55 至 0.98;P=0.036)。作者认为这些结果支持在瓣膜手术患者中采用以生理评估指导的选择性外科冠状动脉血运重建策略。

要点

  • 瓣膜手术合并冠心病患者中,以血管造影衍生 FFR≤0.80 指导 CABG 较造影狭窄≥50% 指导者,30 天复合终点 7.8% vs 13.4%(RR 0.58,95%CI 0.38 至 0.89;P=0.011)。
  • 生理指导组仅 56%(223 例)行同期 CABG,解剖指导组 98%(388 例)行同期 CABG,提示生理评估可安全减少同期 CABG 数量。
  • 30 天死亡:生理指导组 2.8%(11 例)vs 解剖指导组 4.3%(17 例),原文未报告该单项的统计学检验。
  • 中位随访 27 个月,关键次要终点生理指导组 20.7% vs 解剖指导组 26.8%(HR 0.74,95%CI 0.55 至 0.98;P=0.036)。
  • 主要终点分析采用改良意向性治疗人群,即全部随机分组、接受手术且有主要终点数据的患者;解剖指导组 1 例拒绝手术被排除。

适用人群与场景

  • 年龄≥18 岁、计划行瓣膜手术、且至少一支主要冠状动脉存在临床显著狭窄的患者。
  • 研究在中国 12 家三级医院开展,纳入时间为 2019 年 8 月 4 日至 2024 年 8 月 13 日。
  • 改良意向性治疗人群为全部随机分组、接受手术且有主要终点数据的患者;解剖指导组 1 例拒绝手术被排除。
  • 随机分组按中心分层、固定区组长度为 4。

诊断标准与关键阈值

  • 生理指导 CABG 的阈值:血管造影衍生 FFR 值≤0.80 的病变。
  • 解剖指导 CABG 的阈值:冠状动脉造影示狭窄直径≥50% 的病变。
  • 主要终点为术后 30 天内死亡、心肌梗死、卒中、非计划冠状动脉血运重建和需透析的新发肾衰竭的复合终点。
  • 关键次要终点为至少随访 1 年时的死亡、心肌梗死、卒中、非计划冠状动脉血运重建和因不稳定型心绞痛或心力衰竭住院的复合终点。
  • 主要终点缺失数据计划采用完整病例分析或多重插补分析,缺失数据比例阈值为 2%。

处置流程与药物剂量

  • 生理指导组:对血管造影衍生 FFR≤0.80 的病变行 CABG。
  • 解剖指导组:对冠状动脉造影示狭窄直径≥50% 的病变行 CABG。
  • 两组均在接受瓣膜手术的同时行 CABG;生理指导组 223 例(56%)行同期 CABG,解剖指导组 388 例(98%)行同期 CABG。

研究设计与关键结果

  • 研究类型:研究者发起的多中心、随机、三盲试验,12 家中国三级医院,样本量 793 例(生理指导组 396 例,解剖指导组 397 例)。
  • 人群特征:中位年龄 65 岁(IQR 59-70),女性 221 例(28%),男性 571 例(72%)。
  • 主要终点(30 天复合终点):生理指导组 31 例(7.8%)vs 解剖指导组 53 例(13.4%),绝对差异 -5.6 个百分点(95%CI -9.9 至 -1.3),RR 0.58(95%CI 0.38 至 0.89),P=0.011。
  • 30 天死亡:生理指导组 11 例(2.8%)vs 解剖指导组 17 例(4.3%)。
  • 关键次要终点:中位随访 27 个月(生理指导组 28 个月[IQR 18-44],解剖指导组 27 个月[IQR 18-42]),生理指导组 82 例(20.7%)vs 解剖指导组 106 例(26.8%),HR 0.74(95%CI 0.55 至 0.98),P=0.036。

证据类型、等级与局限

  • 证据类型:多中心、三盲、随机对照试验(FAVOR IV-QVAS),注册号 NCT03977129,延长随访正在进行中。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在瓣膜手术合并冠心病的患者中,以血管造影衍生 FFR 行生理指导的 CABG 较解剖指导降低围手术期复合终点发生率。
  • 作者认为,这些发现支持在瓣膜手术患者中采用以生理评估指导的选择性外科冠状动脉血运重建策略。
  • 生理指导组同期 CABG 比例(56%)低于解剖指导组(98%),提示按 FFR≤0.80 筛选可减少同期 CABG 的病变数量。

指南或共识出处

  • FAVOR IV-QVAS 试验,注册于 ClinicalTrials.gov(NCT03977129),发表于 The Lancet。
  • 资助:上海申康医院发展中心、上海市科学技术委员会、中华人民共和国科学技术部。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: For patients undergoing surgical valve procedures with concomitant coronary artery disease, current guidelines recommend that coronary artery bypass grafting (CABG) should be anatomically guided on the basis of stenosis severity, as assessed by coronary angiography. We aimed to test whether a physiologically guided strategy using angiography-derived fractional flow reserve (FFR) could improve clinical outcomes in this population.

METHODS: FAVOR IV-QVAS is an investigator-initiated, multicentre, randomised, triple-blind trial done at 12 tertiary hospitals in China. Eligible patients were aged 18 years or older and were scheduled for valve surgery, with at least one clinically significant stenosis in a major coronary artery. Patients were randomly assigned (1:1) to undergo physiologically guided CABG (for lesions with an angiography-derived FFR value ≤0·80) or anatomically guided CABG (for lesions with a stenosis diameter ≥50% on coronary angiography). Randomisation was done using a web-based program and stratified by site with fixed blocks of four. Patients, surgeons, follow-up physicians, and outcome assessors were masked to treatment allocation. The primary outcome was a composite of death, myocardial infarction, stroke, unplanned coronary revascularisation, and new renal failure requiring dialysis within 30 days after surgery. The key secondary outcome was a composite of death, myocardial infarction, stroke, unplanned coronary revascularisation, and hospitalisation for unstable angina or heart failure at a minimum follow-up of 1 year. The primary analysis of the primary and key secondary outcomes was done in a modified intention-to-treat population that included all randomly assigned patients who underwent surgery and had available data for the primary outcome. Missing data for the primary outcome were planned to be analysed using complete-case analysis or multiple imputation, with a proportion of missing data of 2% as the threshold. This trial is registered at ClinicalTrials.gov (NCT03977129); extended follow-up is ongoing.

FINDINGS: Between Aug 4, 2019, and Aug 13, 2024, 793 patients were enrolled. 396 were randomly assigned to the angiography-derived FFR group and 397 to the coronary angiography group; one patient in the coronary angiography group declined surgery and was excluded from the modified intention-to-treat population. The median age was 65 years (IQR 59-70), 221 (28%) patients were female, and 571 (72%) were male. Concomitant CABG was done in 223 (56%) patients in the angiography-derived FFR group and in 388 (98%) patients in the coronary angiography group. The primary outcome occurred in 31 (7·8%) patients in the angiography-derived FFR group and 53 (13·4%) in the coronary angiography group (absolute difference -5·6 percentage points [95% CI -9·9 to -1·3]; risk ratio 0·58 [95% CI 0·38 to 0·89]; p=0·011). Death within 30 days occurred in 11 (2·8%) patients in the angiography-derived FFR group and 17 (4·3%) patients in the coronary angiography group. At a median follow-up of 27 months (28 months [IQR 18-44] in the angiography-derived FFR group and 27 months [18-42] in the coronary angiography group), the key secondary outcome occurred in 82 (20·7%) patients in the angiography-derived FFR group and in 106 (26·8%) patients in the coronary angiography group (hazard ratio 0·74 [95% CI 0·55-0·98]; p=0·036).

INTERPRETATION: Among patients undergoing valve surgery with concomitant coronary artery disease, physiologically guided CABG using angiography-derived FFR reduced the incidence of the composite perioperative outcome compared with anatomically guided CABG. These findings support a selective approach to surgical coronary revascularisation guided by physiological assessment in patients undergoing valve procedures.

FUNDING: Shanghai Hospital Development Center, Shanghai Municipal Science and Technology Commission, and Ministry of Science and Technology of the People's Republic of China.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Zhu Y, Cheng Z, Zhao Y, et al. Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial. Lancet. 2026. PMID: 41864747. doi:10.1016/S0140-6736(25)02418-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。